A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Leflunomide (Arava)

Leflunomide Tablets, USP are indicated for the treatment of adults with active rheumatoid arthritis (RA).

First FDA approval1998-09-10
Generic availableYes · 9 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$54.0M in CY2024 Part D spend873K claims · 272K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.288/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.309
Across all dosage forms in distribution.
Highest NADAC
$0.330
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Leflunomide used for?

Leflunomide Tablets, USP are indicated for the treatment of adults with active rheumatoid arthritis (RA).

Is there a generic for Leflunomide?

Yes. 18 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Leflunomide?

Across 329 Part D plans, Leflunomide averages $0.309/unit (NADAC). Lowest available: $0.288/unit. Highest in distribution: $0.330/unit.

Is Leflunomide on the FDA shortage list?

No. Leflunomide is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antirheumatic Agent1 alternative in D1
01
Penicillamine
Brand: AAGYLUR
Lowest NADAC
8Generic mfrs
$15.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.